Founder/Director John Simard Buys 368,524 XBIT Shares for $711,251 From Thorpe McKenzie
XBIT is trading near its 52-week low of $1.8 (1.4% above the low).
Summary
XBiotech director and 10% owner John Simard bought 368,524 shares at $1.93 for $711,251 from Thorpe McKenzie, raising his direct holdings to 4,191,690 shares. The purchase comes days after his son was named Co-CEO and follows positive Phase II data.
Key Events · Ownership and Investor Activity · XBIT
-
Director Buys 368,524 Shares
John Simard acquired 368,524 shares at $1.93 for $711,251 on 2026-10-26, per the Form 4.
-
Block Purchased From Thorpe McKenzie
The filing's remarks state the shares were purchased from Thorpe McKenzie, so the block changed hands between holders rather than being bought in the open market.
-
Stake Rises to 4,191,690 Shares
Post-transaction direct holdings are 4,191,690 shares, all directly owned.
-
Follows Co-CEO Appointment
Comes two days after the 2026-10-26 8-K naming Dr. Sushma Shivaswamy and Jan-Paul Simard, the founder's son, as Co-CEOs effective October.
Analysis · XBIT · Life Sciences
Simard, a director and 10% owner, paid $1.93 per share for 368,524 shares — $711,251 of his own money, lifting his direct stake to 4,191,690 shares. The filing states the shares came from Thorpe McKenzie rather than the open market, so this is a transfer of a block between holders, not fresh buying pressure; still, the founder adding to his position at a price above today's $1.825 quote is a real-money vote of confidence. It lands days after the 2026-10-26 8-K naming his son Jan-Paul Simard as Co-CEO and a week after positive Phase II vilamakitug data, so the family is consolidating ownership while the stock trades near its 52-week low of $1.80.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIT was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $1.80 to $3.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.